CN Patent

CN118354781A — 白介素-23受体的肽抑制剂

Assigned to Zealand Pharma AS · Expires 2024-07-16 · 2y expired

What this patent protects

本发明涉及作为白介素‑23受体(IL‑23R)的肽抑制剂的化合物，以及涉及其在治疗或预防多种疾病、病症或障碍中的用途，所述疾病、病症或障碍包括炎性疾病，例如炎性肠病，例如克罗恩病、银屑病和溃疡性结肠炎。所述化合物在胃肠道中具有良好的物理和化学稳定性。

USPTO Abstract

本发明涉及作为白介素‑23受体(IL‑23R)的肽抑制剂的化合物，以及涉及其在治疗或预防多种疾病、病症或障碍中的用途，所述疾病、病症或障碍包括炎性疾病，例如炎性肠病，例如克罗恩病、银屑病和溃疡性结肠炎。所述化合物在胃肠道中具有良好的物理和化学稳定性。

Drugs covered by this patent

Patent Metadata

Patent number: CN118354781A
Jurisdiction: CN
Classification: —
Expires: 2024-07-16
Drug substance claim: No
Drug product claim: No
Assignee: Zealand Pharma AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.